Verily and GlaxoSmithKline have partnered to form Galvani Bioelectronics, a new company which will focus on the research, development, and commercialization of bioelectronics. One of the first projects will be to develop a precision device that can fix type 2 diabetes.
Verily, formerly known as Google Life Sciences, is partnering with GlaxoSmithKline (GSK) to develop bioelectronic medicines that can “harness electrical signals in the body to treat chronic disease.”
The collaboration marries GSK’s pharmaceutical expertise with Verily’s prowess in developing tiny low power electronics. The unification will result in a new company called Galvani Bioelectronics, after Italian scientist Luigi Aloisio Galvani who was an early pioneer of bioelectricity.
Comments are closed.